Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06449183 · ClinicalTrials.gov registry record · NA
VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)
A NA study, sponsored by BioMérieux.
- Completed
- Registry status
- NA
- Development phase
- 903
- Enrollment target
NCT06449183: Completed NA study, sponsored by BioMérieux.
NCT06449183 is a NA study that has completed, run by BioMérieux. The registered enrollment target is 903 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06449183, a NA study, has completed, sponsored by BioMérieux.
- COMPLETED
- Registry status
- NA
- Development phase
- 903 participants
- Enrollment target
Study Summary
Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.
Interventions
- DIAGNOSTIC_TEST VIDAS® TBI Test [GFAP and UCH-L1 assays]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 903 participants |
| Start Date | 2024-05-16 |
| Est. Completion | 2025-11-12 |
| Phase | NA |
What the finished NCT06449183 record still lists
NCT06449183 is an interventional study that assigns participants to a tested intervention. The registered 903 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 1 intervention - of which VIDAS® TBI Test [GFAP and UCH-L1 assays] is the first listed.
NCT06449183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06449183 about?
NCT06449183 is a clinical study titled "VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)". Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessme...
What is the current status of trial NCT06449183?
This trial is currently completed. It is a NA study. The enrollment target is 903 participants. The study started on 2024-05-16. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06449183?
The interventions under investigation include: VIDAS® TBI Test [GFAP and UCH-L1 assays] (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06449183?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06449183's enrollment target sits among peer trials
903 124th of 2000 higher than 1,877 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI